209 related articles for article (PubMed ID: 19194545)
21. Desensitization Protocol in Recipients of Deceased Kidney Donor With Donor-Specific Antibody-Low Titers.
Kanter Berga J; Sancho Calabuig A; Gavela Martinez E; Puig Alcaraz N; Avila Bernabeu A; Crespo Albiach J; Molina Vila P; Beltrán Catalan S; Pallardó Mateu L
Transplant Proc; 2016 Nov; 48(9):2880-2883. PubMed ID: 27932097
[TBL] [Abstract][Full Text] [Related]
22. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
[TBL] [Abstract][Full Text] [Related]
23. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.
Vo AA; Choi J; Cisneros K; Reinsmoen N; Haas M; Ge S; Toyoda M; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2014 Aug; 98(3):312-9. PubMed ID: 24770617
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients.
Green H; Nesher E; Aizner S; Israeli M; Klein T; Zakai H; Rahamimov R; Rozen-Zvi B; Mor E
Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818
[TBL] [Abstract][Full Text] [Related]
25. Acute antibody-mediated rejection in paediatric renal transplant recipients.
Kranz B; Kelsch R; Kuwertz-Bröking E; Bröcker V; Wolters HH; Konrad M
Pediatr Nephrol; 2011 Jul; 26(7):1149-56. PubMed ID: 21461632
[TBL] [Abstract][Full Text] [Related]
26. Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption.
Kälble F; Süsal C; Pego da Silva L; Speer C; Benning L; Nusshag C; Pham L; Tran H; Schaier M; Sommerer C; Beimler J; Mehrabi A; Zeier M; Morath C
Front Med (Lausanne); 2021; 8():781491. PubMed ID: 34977083
[TBL] [Abstract][Full Text] [Related]
27. Posttransplant immunosuppression in highly sensitized patients.
Akalin E
Contrib Nephrol; 2009; 162():27-34. PubMed ID: 19001811
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab.
Vo AA; Petrozzino J; Yeung K; Sinha A; Kahwaji J; Peng A; Villicana R; Mackowiak J; Jordan SC
Transplantation; 2013 Mar; 95(6):852-8. PubMed ID: 23511212
[TBL] [Abstract][Full Text] [Related]
29. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
Kimball PM; McDougan FA; King A
Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
[TBL] [Abstract][Full Text] [Related]
30. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy.
Sonnenday CJ; Warren DS; Cooper M; Samaniego M; Haas M; King KE; Shirey RS; Simpkins CE; Montgomery RA
Am J Transplant; 2004 Aug; 4(8):1315-22. PubMed ID: 15268734
[TBL] [Abstract][Full Text] [Related]
31. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
32. [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].
Rufino Hernández JM; Cabello Moya E; González-Posada JM; Hernández Marrero D; Pérez Tamajón L; Marrero Miranda D; García Rebollo S; Martín Urcuyo B; Rodríguez Hernández A; Franco Maside A; Barrios del Pino Y; Rodríguez Rodríguez R; Maceira Cruz B; Torres Ramírez A; Salido Ruiz E
Nefrologia; 2010; 30(2):252-7. PubMed ID: 20098463
[TBL] [Abstract][Full Text] [Related]
33. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
[TBL] [Abstract][Full Text] [Related]
34. Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy.
Silvestre C; Furian L; Marson P; Tison T; Valente M; Marchini F; Rossi B; Bonfante L; Valerio F; Cozzi E; Rigotti P
Transplant Proc; 2014 Sep; 46(7):2209-13. PubMed ID: 25242753
[TBL] [Abstract][Full Text] [Related]
35. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
[TBL] [Abstract][Full Text] [Related]
36. Rituximab in highly sensitized kidney transplant recipients.
Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Antibody-Mediated Rejection After Kidney Transplantation: Immunological Effects, Clinical Response, and Histological Findings.
de Sousa MV; Gonçalez AC; de Lima Zollner R; Mazzali M
Ann Transplant; 2020 Nov; 25():e925488. PubMed ID: 33199675
[TBL] [Abstract][Full Text] [Related]
38. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
Hirai T; Kohei N; Omoto K; Ishida H; Tanabe K
Transpl Int; 2012 Sep; 25(9):925-34. PubMed ID: 22764746
[TBL] [Abstract][Full Text] [Related]
39. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
Naciri Bennani H; Daligault M; Noble J; Bardy B; Motte L; Giovannini D; Emprou C; Fiard G; Imerzoukene F; Bourdin A; Masson D; Janbon B; Malvezzi P; Rostaing L; Jouve T
J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
[TBL] [Abstract][Full Text] [Related]
40. Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of
Zhu L; Guo Z; Zhao D; Sa R; Zhao G; Guo H; Chen G
Front Immunol; 2022; 13():1087597. PubMed ID: 36713391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
